ReviewTherapeutic advances in chronic disease2014
Pharmacotherapy for obesity: novel agents and paradigms.
Review in Therapeutic advances in chronic disease, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 2 syntheses or guidelines pooled it, 92 citations in OpenAlex.
- Incidence of Post-operative Gastro-esophageal Reflux Disorder in Patients Undergoing Laparoscopic Sleeve Gastrectomy: A Systematic Review and Meta-analysis.Obesity surgery · 2024Pooled it
- Management of obesity after spinal cord injury: a systematic review.The journal of spinal cord medicine · 2017Pooled it
- Pharmacogenetics of amfepramone in healthy Mexican subjects reveals potential markers for tailoring pharmacotherapy of obesity: results of a randomised trial.Scientific reports · 2019Trial
- The Impact of Vertical Sleeve Gastrectomy on Behavioral and Reward-Related Outcomes.Brain and behavior · 2026Article
- Impact on Metabolism Generated by Surgical and Pharmacological Interventions for Weight Loss in Women with Infertility.Metabolites · 2025Review
- Hormonal Imbalance in Obesity and Arthritis: Points of Contact.Current rheumatology reviews · 2025Review
- Short-term Intensive Lifestyle Therapy in a Worksite Setting Improves Cardiometabolic Health in People With Obesity.Journal of the Endocrine Society · 2023Article
- Hypolipidemic, anti-inflammatory, and anti-atherosclerotic effects of tea before and after microbial fermentation.Food science & nutrition · 2021Article
- Mitochondrial uncoupler BAM15 reverses diet-induced obesity and insulin resistance in mice.Nature communications · 2020Article
- Pharmacologic therapy of obesity: mechanisms of action and cardiometabolic effects.Annals of translational medicine · 2019Review
- Pathobiological mechanisms underlying metabolic syndrome (MetS) in chronic obstructive pulmonary disease (COPD): clinical significance and therapeutic strategies.Pharmacology & therapeutics · 2019Review
- Octacosanol and policosanol prevent high-fat diet-induced obesity and metabolic disorders by activating brown adipose tissue and improving liver metabolism.Scientific reports · 2019Article
- Clinical Practice Recommendations for the Management of Obesity in the United Arab Emirates.Obesity facts · 2018Review
- Assessment of Weight Management Practices among Adults in the United Arab Emirates.Journal of nutrition and metabolism · 2017Article
- Addressing Pediatric Obesity in Ambulatory Care: Where Are We and Where Are We Going?Current obesity reports · 2016Review
- Ribose Accelerates Gut Motility and Suppresses Mouse Body Weight Gaining.International journal of biological sciences · 2016Article
- Obesity Education Strategies for Cancer Prevention in Women's Health.Current obstetrics and gynecology reports · 2015Article
- Liraglutide prevents fast weight gain and β-cell dysfunction in male catch-up growth rats.Experimental biology and medicine (Maywood, N.J.) · 2015Article
- Article
- Novel lipidized analogs of prolactin-releasing peptide have prolonged half-lives and exert anti-obesity effects after peripheral administration.International journal of obesity (2005) · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Public health initiatives focused on obesity prevention and lifestyle intervention programmes for patients with obesity have struggled to contain the obesity epidemic to date. In recent years, antiobesity drug therapies have had a limited role in clinical treatment algorithms for patients with obesity. Indeed, a number of high-profile antiobesity drug suspensions have markedly impacted upon the landscape of obesity pharmacotherapy. In this review, we discuss the advent of an increasing array of pharmacotherapeutic agents, which are effective both in inducing weight loss and in maintaining weight loss achieved by lifestyle measures. The development of these drugs as antiobesity agents has followed varying paths, ranging from lorcaserin, a selective serotonin agent, exploiting the beneficial central actions of fenfluramine but without the associated systemic side effects, to liraglutide, a gut hormone already used as a glucose-lowering drug but with appetite-suppressant properties, or the novel drug combination of phentermine/topiramate, two 'old' drugs used in lower doses than with previous therapeutic uses, resulting in an additive effect on weight loss and fewer side effects. We summarize the key findings from recent randomized controlled trials of these three drugs. Although these agents lead to clinically important weight loss when used as monotherapy, the use of antiobesity drugs as adjunctive therapy post intensive lifestyle intervention could prove to be the most successful strategy. Moreover, a progressive approach to obesity pharmacotherapy perhaps offers the best opportunity to finally address the obesity crisis on a mass scale.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.